Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-

ATEMPT 2.0: Adjuvant T-DM1 Vs TH

First Posted Date
2021-05-19
Last Posted Date
2024-11-15
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
500
Registration Number
NCT04893109
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

🇺🇸

Smilow Cancer Hospital Care center at Derby, Derby, Connecticut, United States

🇺🇸

Smilow Cancer Hospital Care center at Fairfield, Fairfield, Connecticut, United States

and more 46 locations

RegoNivo vs Standard of Care Chemotherapy in AGOC

First Posted Date
2021-05-10
Last Posted Date
2024-05-16
Lead Sponsor
Australasian Gastro-Intestinal Trials Group
Target Recruit Count
450
Registration Number
NCT04879368
Locations
🇦🇺

Austin Health, Melbourne, Victoria, Australia

🇦🇹

Medizinische Universitaet Wien, Vienna, Austria

🇦🇹

Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria

and more 91 locations

A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

First Posted Date
2021-05-03
Last Posted Date
2024-04-25
Lead Sponsor
Akeso
Target Recruit Count
50
Registration Number
NCT04868708
Locations
🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

First Posted Date
2021-04-29
Last Posted Date
2024-10-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
130
Registration Number
NCT04865289
Locations
🇨🇳

Fudan University Shanghai Cancer Center ( Site 2500), Shanghai, Shanghai, China

🇨🇳

Women s Hospital School of Medicine Zhejiang University ( Site 2511), Hangzhou, Zhejiang, China

🇨🇳

Anhui Cancer Hospital-Gynecological Oncology ( Site 2509), Hefei, Anhui, China

and more 19 locations

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

First Posted Date
2021-04-26
Last Posted Date
2024-05-17
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
35
Registration Number
NCT04858269
Locations
🇺🇸

Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States

Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2021-04-13
Last Posted Date
2024-12-09
Lead Sponsor
Suzhou Junde Biotechnology Co., Ltd
Target Recruit Count
108
Registration Number
NCT04843098
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath